LEADER 02580nam  2200601   450 
001 9910460617803321
005 20200520144314.0
010   $a0-309-31001-6
035   $a(CKB)3710000000336166
035   $a(EBL)3379407
035   $a(SSID)ssj0001467018
035   $a(PQKBManifestationID)11892276
035   $a(PQKBTitleCode)TC0001467018
035   $a(PQKBWorkID)11504063
035   $a(PQKB)11321513
035   $a(MiAaPQ)EBC3379407
035   $a(Au-PeEL)EBL3379407
035   $a(CaPaEBR)ebr11003355
035   $a(OCoLC)904080937
035   $a(EXLCZ)993710000000336166
100   $a20150121h20142014  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aCharacterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products $eworkshop summary /$fDenise Caruso, Rebecca A. English, Anne B. Claiborne
210  1$aWashington, District of Columbia :$cThe National Academies Press,$d2014.
210  4$dİ2014
215   $a1 online resource (150 p.)
300   $aDescription based upon print version of record.
311   $a0-309-31000-8 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""Boxes, Figures, and Table""; ""Acronyms""; ""1 Introduction""; ""2 Identifying and Characterizing Uncertainty""; ""3 The Regulators Challenge""; ""4 Basic Methodologies and Applications for Understanding and Evaluating Uncertainty""; ""5 Communicating Uncertainty""; ""6 Final Reflections on Ways to Characterize and Communicate Uncertainty""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: FDA Case Studies""; ""Appendix C: Bibliography""; ""Appendix D: Participant Biographies""
606   $aRisk assessment$vCongresses
606   $aCommunication$vCongresses
608   $aElectronic books.
615  0$aRisk assessment
615  0$aCommunication
676   $a363.1
700   $aCaruso$b Denise$0928102
702   $aEnglish$b Rebecca A.
702   $aClaiborne$b Anne B.
712 02$aBoard on Health Sciences Policy.
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
712 02$aInstitute of Medicine (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910460617803321
996   $aCharacterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products$92085694
997   $aUNINA